GSK secures rights to Syndivia’s ADC asset for prostate cancer

GlaxoSmithKline (GSK) has struck a deal to acquire exclusive rights to develop and commercialise an antibody-drug conjugate (ADC) from Syndivia targeting metastatic castration-resistant prostate cancer. The agreement is reported to be worth up to £268 million, reflecting GSK’s push to broaden its oncology pipeline.

Syndivia, a France-based biotech firm specialising in next-generation ADCs through its proprietary platform, has shown this candidate delivered enhanced tumour reduction in preclinical studies while maintaining an encouraging safety profile. GSK noted the therapy addresses a significant unmet need given the limited targeted treatment options for this advanced form of prostate cancer.

Under the terms of the transaction, Syndivia will receive an upfront payment, followed by additional development and commercial milestone payments contingent on progress. For GSK the move marks another strategic step in its oncology growth agenda and complements its recent strong performance in the specialty medicines space.

The acquisition also arrives at a time of leadership transition at GSK, with outgoing chief executive Emma Walmsley overseeing the deal ahead of her stepping down, which adds a layer of timing interest to the transaction. Overall the deal bolsters both companies: Syndivia gains backing and scale for its asset, while GSK acquires a promising preclinical oncology therapy to drive future value.